Advanced Lung Adenocarcinoma with EGFR Exon 20 Insertional Mutation Treated with Furmonertinib: A Report of 2 Cases

Xiang Y, Liu J, Sun A and Lu K

Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, China

^*Correspondance to: Kaihua Lu 

 PDF  Full Text Case Series | Open Access

Abstract:

Epidermal Growth Factor Receptor (EGFR) exon 20 insertion (ex20ins) mutations account for approximately 0.1% to 4% of all Non-Small Cell Lung Cancers (NSCLC) and 4% to 12% of all EGFR mutations. Since patients with EGFR ex20ins usually respond poorly to 1st- and 2ndgeneration EGFR Tyrosine Kinase Inhibitors (EGFR-TKIs), treatment options for this group of patients remain a headache. Here, we report two cases of lung adenocarcinoma patients with EGFR ex20ins mutation treated with furmonertinib (160 mg daily), both achieved Partial Response (PR) at the initial efficacy assessment with no specific adverse effects. One of them had Progression-Free Survival (PFS) of more than 12 months. Unfortunately, the other had a PFS of only 5.2 months with the same regimen, which may be related to the high heterogeneity of EGFR ex20ins or the coexistence of TP53 co-mutations. In any case, this case report presents a new and possible option for NSCLC patients with EGFR ex20ins mutations.

Keywords:

Furmonertinib; Exon-20 insertion mutation; Epidermal growth factor receptor; Non-small cell lung cancer; Next-generation sequencing

Cite the Article:

Xiang Y, Liu J, Sun A, Lu K. Advanced Lung Adenocarcinoma with EGFR Exon 20 Insertional Mutation Treated with Furmonertinib: A Report of 2 Cases. Clin Oncol. 2023;8:2033..